Home Biosimilar Antibodies Protein Tyrosine Kinase HER2 Patritumab (Anti-ERBB3 / HER3)
For research use only. Not for use in humans.

Patritumab (Anti-ERBB3 / HER3)

Synonyms: Human Anti-ERBB3 Recombinant Antibody

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

Patritumab (Anti-ERBB3 / HER3)

Click to purchase the isotype control of Patritumab (Anti-ERBB3 / HER3)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.181mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation HER2 Others
Canertinib (CI-1033) 51 EGFR
CP-724714 109
Sapitinib (AZD8931) 50 ErbB3,EGFR
CUDC-101 23 EGFR,HDAC,HDAC1
Mubritinib (TAK 165) 41
AEE788 (NVP-AEE788) 16 EGFR,c-Abl,FLT1
AC480 (BMS-599626) 12 HER1,HER4
TAK-285 5 EGFR/HER1,HER4,MEK1
Tyrphostin AG 879 3 Trk
Tuxobertinib (BDTX-189) 3 EGFR,RIPK2,BLK
Epertinib hydrochloride 1 EGFR,HER4
TAS0728 1
Tyrphostin AG-528 0 EGFR
SU5204 1 VEGFR-2
Pyrotinib dimaleate 6 EGFR
Poziotinib (NOV120101, HM781-36B) 37 HER1,HER4
HER2-Inhibitor-1 1
Zongertinib (BI 1810631) 1 EGFR-Ex20ins
Nordihydroguaiaretic acid (NDGA) 2 p300,IGF-1R,lipoxygenase
EGCG ((-)-Epigallocatechin Gallate) 42 FASN,EGFR,DNMT
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

Product Details

CAS No. 1262787-83-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07060807 RECRUITING Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug: Capecitabine|Dru Breast Neoplasms Merck Sharp & Dohme LLC 2025-07-21 PHASE3
NCT06731907 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug Non-small Cell Lung Cancer Merck Sharp & Dohme LLC 2025-03-30 PHASE2
NCT04165070 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme LLC 2019-12-19 PHASE1; PHASE2
NCT05919537 ACTIVE_NOT_RECRUITING Drug: HMBD-001|Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Ge Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor Hummingbird Bioscience 2023-09-06 PHASE1
NCT07701941 NOT_YET_RECRUITING Drug: Patritumab deruxtecan|Drug: Trastuzumab deruxtecan Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer Daiichi Sankyo 2026-08-03 PHASE1; PHASE2
NCT06941272 RECRUITING Malignant Neoplasm Merck Sharp & Dohme LLC 2025-05-26 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-28)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.